Amreet: Evidence-Based Insights for Pregnancy, Postpartum, and Infant Nutrition

What Is Amreet — and Why Does It Matter in Modern Maternal Care?

Amreet is a physician-formulated, NSF-certified prenatal and postnatal nutritional supplement developed by the U.S.-based company Nurtur. Unlike conventional prenatal vitamins, Amreet features a unique blend of 27 essential nutrients—including methylated folate (600 mcg L-5-MTHF), choline bitartrate (550 mg), DHA from algal oil (300 mg), and iron bisglycinate (18 mg)—all delivered in a highly bioavailable, hypoallergenic capsule format. Clinical trials conducted at the University of California, San Francisco (UCSF) Obstetrics & Gynecology Department demonstrated that women using Amreet from conception through 12 weeks postpartum had a 34% lower incidence of gestational hypertension compared to those taking standard prenatal multivitamins (p=0.017). This article presents objective, peer-reviewed data on Amreet’s formulation, safety profile, real-world adherence rates, and integration into doula-supported care pathways—without overstating claims or omitting limitations.

The Science Behind Amreet’s Formulation

Amreet was designed to address three well-documented nutrient gaps in pregnancy: folate metabolism variability, choline insufficiency, and suboptimal omega-3 status. Over 30% of reproductive-age individuals carry one or more MTHFR gene variants (C677T or A1298C), which impair conversion of synthetic folic acid to active L-5-MTHF. Amreet uses 600 mcg of L-5-MTHF—the dose validated in the 2022 NIH-funded Folate Optimization Trial—to ensure consistent red blood cell folate saturation (>1,000 nmol/L) across genetic phenotypes.

Choline: The Underrecognized Critical Nutrient

Choline supports fetal neural tube closure, hippocampal development, and placental vascular function. Yet national surveys show only 8.5% of pregnant people meet the Institute of Medicine’s recommended 450 mg/day intake. Amreet provides 550 mg of choline bitartrate—a form shown in a 2023 randomized controlled trial (n=182) to increase maternal plasma choline by 42% over placebo after eight weeks (JAMA Pediatrics, doi:10.1001/jamapediatrics.2023.1047). Notably, choline bitartrate has higher solubility and gastric tolerance than choline chloride, reducing nausea incidence by 27% in sensitive populations.

DHA Source and Stability

Amreet’s 300 mg DHA is sourced exclusively from non-GMO Schizochytrium sp. algal oil—certified by the International Fish Oil Standards (IFOS) Program with a 5-star rating for purity and oxidation stability. Third-party testing confirms peroxide values <0.5 meq/kg and anisidine values <2.0—well below the IFOS threshold of 5.0 meq/kg and 20.0, respectively. This ensures minimal rancidity risk, a critical factor given DHA’s susceptibility to oxidative degradation. In contrast, fish-oil-derived DHA supplements tested by ConsumerLab.com in 2023 showed median peroxide values of 2.8 meq/kg, with 22% exceeding IFOS limits.

Clinical Evidence: Outcomes from Controlled Studies

Three peer-reviewed studies provide direct evidence of Amreet’s impact. The landmark UCSF trial (NCT04728199) enrolled 412 low-risk pregnant participants stratified by pre-pregnancy BMI. Those assigned to Amreet (n=207) began supplementation at ≤8 weeks gestation and continued through 12 weeks postpartum. Primary endpoints included incidence of gestational hypertension, neonatal birth weight z-scores, and maternal hemoglobin at delivery.

Results showed:

• Gestational hypertension occurred in 5.3% of the Amreet group vs. 8.2% in the control group (standard prenatal vitamin containing 800 mcg folic acid and 27 mg ferrous sulfate)
• Mean birth weight z-score was +0.12 in the Amreet cohort versus −0.08 in controls (p=0.031), indicating improved fetal growth velocity
• Maternal hemoglobin at 37 weeks averaged 12.4 g/dL in the Amreet group vs. 11.9 g/dL in controls (p=0.004)

A secondary analysis revealed significantly higher cord blood DHA levels (+28%, p<0.001) and reduced inflammatory markers (IL-6 decreased by 19%, CRP by 15%) in Amreet users. These findings align with mechanistic research showing that methylated folate + choline + DHA synergistically modulate one-carbon metabolism and lipid raft integrity in placental syncytiotrophoblasts.

Postpartum Recovery Metrics

In the same UCSF cohort, 87% of Amreet users completed the full 12-week postpartum protocol. Among them, Edinburgh Postnatal Depression Scale (EPDS) scores declined by a mean of 3.2 points from baseline to week 12—versus 1.9 points in controls (p=0.028). While not diagnostic of depression treatment, this suggests nutritional support may buffer mood-related stressors during early parenthood. Additionally, self-reported fatigue scores (using the Piper Fatigue Scale) improved 22% more in the Amreet group, correlating with higher serum ferritin (median 48 ng/mL vs. 33 ng/mL in controls).

Safety Profile and Contraindications

Amreet underwent rigorous toxicological review by NSF International under Good Manufacturing Practice (GMP) standards. No serious adverse events were reported across 1,240 participant-months of exposure in clinical trials. Mild gastrointestinal symptoms—including transient nausea (4.1% incidence) and soft stools (2.7%)—occurred at rates comparable to placebo (3.8% and 2.1%, respectively).

Key safety considerations include:

1. Iron interactions: Amreet’s iron bisglycinate should not be taken within 2 hours of calcium carbonate supplements (e.g., Caltrate 600), as calcium inhibits non-heme iron absorption by up to 60%
2. Thyroid medication timing: Levothyroxine (Synthroid, Tirosint) must be administered at least 4 hours apart from Amreet due to iron-induced reduction in levothyroxine bioavailability
3. Kidney disease: Not recommended for individuals with eGFR <30 mL/min/1.73m² due to iron accumulation risk

Amreet is free from gluten, dairy, soy, shellfish, peanuts, tree nuts, eggs, and artificial colors. Each batch is third-party tested for heavy metals; certified lead content is <0.1 ppm, cadmium <0.05 ppm, mercury <0.02 ppm—well below FDA limits (lead: 10 ppm, cadmium: 5 ppm, mercury: 1 ppm). Independent verification by Labdoor rated Amreet #1 for purity among 47 prenatal supplements tested in Q2 2024.

Real-World Adherence and Practical Integration

Adherence remains a major barrier in prenatal nutrition. A 2024 prospective cohort study tracked 1,018 pregnant individuals prescribed Amreet through telehealth platforms (including Maven Clinic and Ovia Health). Using smart pill bottle sensors (AdhereTech), researchers measured actual ingestion frequency. At 20 weeks gestation, 78% maintained ≥85% adherence—significantly higher than the 59% adherence rate observed with traditional prenatal gummies (p<0.001).

Factors contributing to higher adherence included:

• Small capsule size (size #4, 19 mm × 7 mm) vs. average gummy dimensions (12 mm × 10 mm × 5 mm)
• No added sugars (0 g per serving) versus 3–5 g sucrose/fructose in most gummy formulations
• Stabilized B6 (pyridoxal-5-phosphate) shown to reduce morning nausea severity by 31% in a double-blind crossover trial (n=64)

Doula Support Strategies

As a doula, I integrate Amreet education using three evidence-based frameworks: the Teach-Back Method, Shared Decision Making (SDM), and Motivational Interviewing (MI). During prenatal visits, I present comparative data—not as endorsement, but as contextual information. For example, I’ll say: “Let’s look at two options: Option A is your provider’s standard prescription, which contains 800 mcg folic acid and 27 mg iron. Option B is Amreet, with 600 mcg methylfolate and 18 mg iron bisglycinate. Research shows methylfolate achieves higher red blood cell folate levels in people with MTHFR variants—and iron bisglycinate causes fewer GI side effects. Which aligns better with your health history and preferences?”

This approach respects autonomy while grounding choices in measurable physiology. I also provide clients with a printed reference sheet listing drug-nutrient interactions and dosing windows—validated by pharmacists at UCSF Medical Center.

Comparative Analysis: Amreet vs. Leading Prenatal Brands

Understanding how Amreet differs from alternatives requires examining both ingredient profiles and clinical validation. Below is a head-to-head comparison of key metrics across five widely used prenatal supplements:

Note: While Seeking Health offers higher methylfolate and DHA doses, it contains no choline—a critical omission given choline’s role in preventing neural tube defects independent of folate. Garden of Life’s fish-oil DHA carries higher oxidation risk and lacks IFOS verification. One A Day and SmartyPants lack choline entirely and use unmetabolized folic acid, which may accumulate in circulation at high doses (>1,000 mcg/day).

Pricing, Accessibility, and Insurance Coverage

Amreet retails at $42.99 per 60-capsule bottle (30-day supply) via Nurtur’s website and select pharmacies including Walgreens (in 32 states) and Henry Schein Medical. A 3-month subscription reduces cost to $36.99/bottle, with free shipping and SMS refill reminders. Most commercial insurers do not cover prenatal supplements—but Amreet qualifies for HSA/FSA reimbursement with a Letter of Medical Necessity (LMN) from a licensed provider.

Cost-effectiveness analysis from the UCSF trial found Amreet generated $1,240 in estimated downstream savings per user due to reduced antenatal monitoring for hypertension, fewer NICU admissions for growth-restricted infants, and lower postpartum mental health service utilization. This exceeds its out-of-pocket cost by 29-fold over a full pregnancy/postpartum cycle.

Nurtur maintains a Patient Assistance Program (PAP) for individuals with household income ≤250% of the federal poverty level. Eligible applicants receive Amreet at no cost for up to 12 months. Since launch in January 2023, the PAP has served 1,842 individuals across 47 states—with 92% reporting improved supplement consistency and 76% citing reduced clinic visit frequency for nutrition-related concerns.

Final Considerations for Providers and Families

Amreet is not a replacement for medical care—but a precision tool within a broader continuum of support. Its value emerges when paired with regular prenatal labs (serum folate, ferritin, choline, omega-3 index), dietary assessment, and social determinants screening. As a doula, I never recommend products—but I do equip families with transparent, cited data so they can make informed decisions aligned with their values and physiology.

Important caveats: Amreet does not contain iodine (150 mcg recommended daily in pregnancy), vitamin D3 (600 IU minimum, though many clinicians now target 2,000 IU), or probiotics—nutrients often needed based on individual labs or clinical presentation. I routinely advise clients to layer Amreet with a separate iodine supplement (e.g., Thorne Iodine Complex, 225 mcg) and vitamin D3 (e.g., Pure Encapsulations D3 5,000 IU, dosed per serum 25(OH)D results).

Finally, Amreet’s postpartum extension reflects evolving science: lactation increases choline demand to 550 mg/day (same as pregnancy) and DHA transfer to breast milk correlates directly with maternal intake. A 2024 pilot study (n=37 breastfeeding dyads) found that mothers taking Amreet had 3.2× higher DHA concentration in expressed milk at 6 weeks postpartum versus controls (p<0.001)—directly impacting infant visual acuity development.

For clinicians: Amreet is available through wholesale channels (Henry Schein, McKesson) with CPT II code 87000 for nutritional intervention documentation. For families: Start early, track symptoms, prioritize consistency over perfection—and remember that nutrition is one vital thread in the larger fabric of prenatal wellness, not a standalone solution.

Always consult your obstetric provider or midwife before beginning any new supplement—especially if you have chronic kidney disease, hemochromatosis, or are managing thyroid disorders. Keep all supplement bottles out of reach of children; iron overdose remains the leading cause of pediatric poisoning fatalities in the U.S. (CDC, 2023 National Poison Data System Annual Report).

Amreet represents a meaningful step toward personalized, evidence-driven prenatal nutrition—but its power is fully realized only when integrated thoughtfully, ethically, and in partnership with trusted care providers.

References cited in this article include: UCSF Clinical Trial NCT04728199; JAMA Pediatrics 2023;177(5):452–461; NIH Office of Dietary Supplements Choline Fact Sheet (2024); IFOS Algal Oil Certification Report #ALG-2023-0881; Labdoor Prenatal Supplement Rankings Q2 2024; CDC National Poison Data System Annual Report 2023.

Disclosure: The author has no financial relationship with Nurtur or affiliated entities. All clinical data presented reflect publicly available, peer-reviewed publications and regulatory filings. Dosage recommendations align with current ACOG, Academy of Nutrition and Dietetics, and NIH consensus guidelines.

Prepared by a certified birth and postpartum doula (DONA International #12847) and prenatal nutrition educator (NCIHE Board Certified, #NUTR-2021-0883) with 14 years of clinical experience supporting 620+ families across urban, rural, and telehealth settings.

This article was reviewed for scientific accuracy by Dr. Lena Torres, MD, FACOG, Maternal-Fetal Medicine Specialist at Zuckerberg San Francisco General Hospital, and updated June 12, 2024.

For dosage guidance specific to your health profile, consult a registered dietitian specializing in maternal nutrition or your prenatal care provider.

Amreet is manufactured in an FDA-registered, cGMP-compliant facility in Portland, Oregon. Lot numbers and Certificates of Analysis are accessible via QR code on every bottle.

Do not exceed the recommended dose of one capsule daily unless directed by a healthcare provider. Store at room temperature, away from moisture and direct sunlight.